JOURNEY MEDICAL CORPOR

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

18 Mar 2022 13:15:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

17 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

09 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

11 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

13 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

10 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference

07 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Introduces Expanded Board of Directors

29 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Closing of Initial Public Offering

16 Nov 2021 16:01:00 By Nasdaq GlobeNewswire